Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as denufosol tetrasodium (INS37217) Intravitreal Injection
denufosol tetrasodium Intravitreal · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| denufosol tetrasodium (INS37217) Intravitreal Injection | DRUG | - |
Inclusion Criteria: * have macula-on or macula-off rhegmatogenous retinal detachment * are eligible for pneumatic retinopexy, with identifiable retinal breaks * are phakic or pseudo-phakic Exclusion Criteria: * have detachments not of a rhegmatogenous nature * currently have blood in the vitreous...
Denufosol tetrasodium Intravitreal is being developed for the treatment of retinal detachment, an ophthalmology condition in which the retina separates from the back of the eye. It is an investigational small molecule administered by intravitreal injection. Development is at Phase 1, so it is not an approved therapy.
Denufosol tetrasodium Intravitreal targets P2RY2, a purinergic receptor. It acts as an agonist at this receptor, meaning it activates P2RY2 signaling. The P2RY2 target class is agonist. This mechanism is being studied in the context of retinal detachment.
Denufosol tetrasodium Intravitreal is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical program for this intravitreal small molecule in retinal detachment.
Denufosol tetrasodium Intravitreal is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program includes one completed trial with 14 participants.
Denufosol tetrasodium Intravitreal has been studied in one clinical trial, NCT00210067, titled A Study in Subjects With Retinal Detachment. This Phase 1 trial is completed and enrolled 14 participants. It was randomized and double-blind with an uncontrolled design.
Yes, denufosol tetrasodium Intravitreal is also known as denufosol tetrasodium (INS37217) Intravitreal Injection. The two names refer to the same investigational small molecule developed by Merck for retinal detachment. INS37217 is an alternate identifier used for this compound.